Vincerx Pharma Inc. (VINCW)
NASDAQ: VINCW
· Real-Time Price · USD
1.61
-0.42 (-20.69%)
At close: May 05, 2021, 9:12 PM
Company Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.
Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer.
The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies.
Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Vincerx Pharma Inc.
| Country | United States |
| IPO Date | May 21, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Hans-Georg Lerchen |
Contact Details
Address: 260 Sheridan Avenue Palo Alto, California United States | |
| Website | https://vincerx.com |
Stock Details
| Ticker Symbol | VINCW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001796129 |
| CUSIP Number | n/a |
| ISIN Number | n/a |
| Employer ID | 83-3197402 |
| SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 29, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jul 16, 2025 | DEFA14A | Filing |
| Jul 07, 2025 | DEFA14A | Filing |
| Jul 07, 2025 | 8-K | Current Report |
| Jun 18, 2025 | DEFA14A | Filing |
| Jun 06, 2025 | DEFA14A | Filing |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 12, 2025 | DEF 14A | Filing |
| May 02, 2025 | EFFECT | Filing |